Author:
Kim Tae You,Yen Chia-Jui,Al-Batran Salah-Eddin,Ferry David,Gao Ling,Hsu Yanzhi,Cheng Rebecca,Orlando Mauro,Ohtsu Atsushi
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Gastroenterology,Oncology,General Medicine
Reference17 articles.
1. Spratlin JL, Cohen RB, Eadens M, Gore L, Camidge DR, Diab S, et al. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol. 2010;28:780–7.
2. Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014;383:31–9.
3. Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014;15:1224–35.
4. US Food and Drug Administration. Cyramza (ramucirumab) injection, for intravenous use: US prescribing information. 2014. http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm426735.htm .
5. European Medicines Agency. Cyramza, summary of product characteristics. 2016. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002829/human_med_001825.jsp&mid=WC0b01ac058001d124 .
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献